Inclusion Criteria:  Males or non-pregnant females (who must agree to use barrier methods of contraception during the study therapy period, women of childbearing age must have a negative urine pregnancy or serum test at baseline). Subjects who are 18 years of age or older. Subjects with at least one positive blood culture isolation of Candida species from a specimen drawn within 96 hours prior to study entry.  Subjects who have clinical evidence of infection sometime within 96 hours prior to enrolment, including at least one of the following:  Temperature >37.8 ˚C on two occasions at least four hours apart or one measurement > 38.2 ˚C Systolic blood pressure <90 or a >30 mmHg decrease in systolic blood pressure from the subject's normal baseline or the need for vasopressive therapy. Signs of inflammation (swelling, heat, erythema, purulent drainage) from a site infected with Candida (e.g. joint, skin, eye, bone, oesophagus). Radiologic findings of invasive candidiasis. Subject or their legal representative must sign a written informed consent form.  Exclusion Criteria:  Subjects with a history of allergy or intolerance to rIFN-γ. Subjects with a history of documented epileptic seizures. Subjects with severe liver failure ((>5x upper limit AST or ALT or impaired synthesis of proteins such as coagulation factors manifested by increased prothrombin time). Women who are pregnant or lactating. Subjects who are unlikely to survive more than 24 hours. Subjects who have failed previous systemic antifungal therapy for the Candida spp. infection which is being studied. Subjects who have received more than 72 hours of systemic antifungal therapy for the current episode, within 96 hours prior to study entry.